Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies

被引：0
|
作者：
Laiyi Chua
Stuart Friedrich
Xin Cindy Zhang
机构：
[1] Eli Lilly and Company,Global PK/PD and Pharmacometrics
来源：
Clinical Pharmacokinetics | 2023年 / 62卷 / 10期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1479 / 1491
页数：12
相关论文
共 50 条
  • [1] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023, : 1479 - 1491
  • [2] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023,
  • [3] EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
    D'Haens, Geert
    Higgins, Peter D.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard
    Redondo, Isabel
    Escobar, Rodrigo
    Morris, Nathan
    Kobayashi, Taku
    GASTROENTEROLOGY, 2023, 164 (06) : S1086 - S1086
  • [4] Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
    D'Haens, G.
    Higgins, P. D. R.
    Peyrin-Biroulet, L.
    Sands, B. E.
    Lee, S.
    Moses, R. E.
    Redondo, I.
    Escobar, R.
    Morris, N.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 682 - 682
  • [5] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
    Andrews, J. M.
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
  • [6] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
    D'Haens, G.
    Kobayashi, T.
    Morris, N.
    Lissoos, T.
    Hoover, A.
    Li, X.
    Arora, V.
    Milch, C.
    Sandborn, W. J.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
  • [7] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
    Dubinsky, Marla C.
    Irving, Peter M.
    Li, Xingyuan
    Howaldt, Stefanie
    Pokrotnieks, Juris
    Krueger, Kathryn A.
    Laskowski, Janelle
    Lissoos, Trevor
    Milata, Joe
    Morris, Nathan
    Arora, Vipin
    Milch, Catherine
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394
  • [8] Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Keohane, A.
    Zhu, B.
    Ritter, T.
    Regueiro, M.
    Hudesman, D.
    Chen, Y. F.
    Owen, C.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1975 - I1976
  • [9] Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Sands, Bruce E.
    Feagan, Brian G.
    Gibble, Theresa Hunter
    Traxler, Kristina A.
    Morris, Nathan
    Eastman, William J.
    Schreiber, Stefan
    Jairath, Vipul
    Long, Millie D.
    Armuzzi, Alessandro
    CROHNS & COLITIS 360, 2023, 5 (04)
  • [10] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S214 - S214
12345